CERC Cerecor Inc.

+0  (4%)
Previous Close 0.51
Open 0.50
Price To book 23.18
Market Cap 5.69M
Shares 10,744,000
Volume 408,803
Short Ratio 1.33
Av. Daily Volume 333,332

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data released December 5, 2016 - endpoint not met.
Smoking cessation
Phase 2 top-line data released November 29, 2016 failed to meet primary endpoint.
Major depressive disorder (MDD)

Latest News

  1. Cerecor Inc. Closes $5.0 Million Private Placement
  2. CERC: Ready to Move Ahead With Phase 2/3 Study of CERC-501 in MDD
  3. Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
  4. Cerecor Engages SunTrust Robinson Humphrey to Assist with Review of Strategic Alternatives
  5. Cerecor Announces At-the-Market Equity Offering Program
  6. Cerecor Nicotine Withdrawal Drug Fails Study (CERC)
  7. Cerecor Inc (CERC)’s Trial Failure Isn’t All Bad, Here’s The Silver Lining
  8. CERC: CERC-501 Not Successful in Nicotine Withdrawal; Preparing for Phase 2/3 Study of CERC-501 in MDD
  9. Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal
  10. Cerecor Depression Drug Fails Phase 2 Trial (CERC)
  11. CERC: CERC-301 Fails to Show Benefit in MDD in Phase 2 Clinical Trial; Attention Now Turns to CERC-501
  12. Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder
  13. CERC: Results from Phase 2 Study of CERC-301 in Major Depressive Disorder to be Announced in November 2016
  14. Cerecor Inc. Reports Third Quarter 2016 Financial Results
  15. Discovery of Cerecor Drug Candidate CERC-611 (LY3130481) Published in Nature Medicine
  16. What To Watch From The Upcoming Cerecor Inc (CERC) Release
  17. Why Traders Are Buzzing About Qualcomm, NXP, Alkermes, Cerecor, and More
  18. Cerecor to Present at the 15th Annual BIO Investor Forum in San Francisco on October 18th, 2016